The antimicrobial activity of Cbf-K16 against MRSA was enhanced by β-lactamantibiotics through cell wall non-integrity
详细信息 查看全文
- 作者：Bo Li ; Wei Kang ; Hanhan Liu ; Yanrong Wang ; Changzhong Yu…
- 刊名：Archives of Pharmacal Research
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：39
- 期：7
- 页码：978-988
- 全文大小：3,164 KB
- 刊物主题：Pharmacy; Pharmacology/Toxicology;
- 出版者：Springer Netherlands
- ISSN：1976-3786
- 卷排序：39
文摘
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as one of the most important pathogens both in health care and in community-onset infections. Cbf-K16, a cathelicidin-like antimicrobial peptide, presented broad antimicrobial activity during our previous studies. We evaluated the potential for synergy of Cbf-K16 with ceftazidime/ampicilin against MRSA, which was resistant to these two antibiotics with the minimum inhibitory concentration more than 64 μg/ml. The combinations showed a synergistic effect by a checkerboard assay with a fractional inhibitory concentration index ≤0.5. The killing curves of the combination treatment against MRSA showed that CFU counts decreased rapidly within 4 h by almost five logs, while single medication groups and the control group exhibited little inhibitory effect. In addition, in a mice bacteremia model, studies indicated that the combination treatment significantly prolonged the survival time of mice infected with MRSA, with a death protection rate of 80 %. Flow cytometry analysis and transmission electron microscopy indicated that combination-treated MRSA was completely ruptured with the cellular contents leaked out. The synergistic effect showed that Cbf-K16 selectively killed cells with non-integrity induced by cell wall inhibition antibiotics, suggesting that Cbf-K16 is a potential therapeutic agent and adjuvant for antimicrobial chemotherapy.KeywordsCbf-K16Antimicrobial activityCeftazidimeAmpicillinMRSASynergistic effect